Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2008

01-02-2008 | Original Paper

Novel Biodegradable Stents for Benign Esophageal Strictures Following Endoscopic Submucosal Dissection

Authors: Yasuharu Saito, Toyohiko Tanaka, Akira Andoh, Hideki Minematsu, Kazunori Hata, Tomoyuki Tsujikawa, Norihisa Nitta, Kiyoshi Murata, Yoshihide Fujiyama

Published in: Digestive Diseases and Sciences | Issue 2/2008

Login to get access

Abstract

The application of metallic stents for benign stenosis is limited due to long-term complications. We report here the results of the implantation of a novel biodegradable poly-l-lactic acid (PLLA) esophageal stent in two patients with benign esophageal stenosis after endoscopic submucosal dissection (ESD). Case 1 was a 64-year-old man who received ESD for an early squamous esophageal cancer in the middle esophagus. The mucosal defect was seven-eighths of the circumference, and the distal margin of the resection scar formed the stenosis. After balloon dilatation, the PLLA esophageal stent was endoscopically placed; for 6 months, he has not experienced any symptoms of re-stenosis. Case 2 consisted of a 62-year-old man who developed an early squamous esophageal cancer in the middle esophagus. The lesion was resected by ESD, and the mucosal defect was seven-eighths of the circumference. The resection scar formed the stenosis, and the PLLA esophageal stent was endoscopically placed. He also has not experienced any symptoms of re-stenosis for 6 months. In conclusion, the PLLA esophageal stent provides a new possibility for the management of benign esophageal strictures after ESD. Due to the biodegradable features of this stent, longer term studies are necessary to investigate the relationship between the expected disappearance of the stent and the patency of the stricture.
Literature
1.
go back to reference Holt AP, Patel M, Ahmed MM (2004) Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc 60:1010–1017PubMedCrossRef Holt AP, Patel M, Ahmed MM (2004) Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc 60:1010–1017PubMedCrossRef
2.
go back to reference Song HY, Do YS, Han YM, Sung KB, Choi EK, Sohn KH, Kim HR, Kim SH, Min YI (1994) Covered, expandable esophageal metallic stent tubes: experiences in 119 patients. Radiology 193:689–695PubMed Song HY, Do YS, Han YM, Sung KB, Choi EK, Sohn KH, Kim HR, Kim SH, Min YI (1994) Covered, expandable esophageal metallic stent tubes: experiences in 119 patients. Radiology 193:689–695PubMed
3.
go back to reference Song HY, Park SI, Do YS, Yoon HK, Sung KB, Sohn KH, Min YI (1997) Expandable metallic stent placement in patients with benign esophageal strictures: results of long-term follow-up. Radiology 203:131–136PubMed Song HY, Park SI, Do YS, Yoon HK, Sung KB, Sohn KH, Min YI (1997) Expandable metallic stent placement in patients with benign esophageal strictures: results of long-term follow-up. Radiology 203:131–136PubMed
4.
go back to reference Ackroyd R, Watson DI, Devitt PG, Jamieson GG (2001) Expandable metallic stents should not be used in the treatment of benign esophageal strictures. J Gastroenterol Hepatol 16:484–487PubMedCrossRef Ackroyd R, Watson DI, Devitt PG, Jamieson GG (2001) Expandable metallic stents should not be used in the treatment of benign esophageal strictures. J Gastroenterol Hepatol 16:484–487PubMedCrossRef
5.
go back to reference Evrard S, Le Moine O, Lazaraki G, Dormann A, El Nakadi I, Deviere J (2004) Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60:894–900PubMedCrossRef Evrard S, Le Moine O, Lazaraki G, Dormann A, El Nakadi I, Deviere J (2004) Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60:894–900PubMedCrossRef
6.
go back to reference Mercer CD, Hill LD (1986) Surgical management of peptic esophageal stricture. Twenty-year experience. J Thorac Cardiovasc Surg 91:371–378PubMed Mercer CD, Hill LD (1986) Surgical management of peptic esophageal stricture. Twenty-year experience. J Thorac Cardiovasc Surg 91:371–378PubMed
7.
go back to reference Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB 3rd (1992) Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20:467–474PubMedCrossRef Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB 3rd (1992) Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20:467–474PubMedCrossRef
8.
go back to reference Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M, Miyata Y (2005) Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 3:S67–S70 PubMedCrossRef Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M, Miyata Y (2005) Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 3:S67–S70 PubMedCrossRef
9.
go back to reference Kulkarni RK, Pani KC, Neuman C, Leonard F (1966) Polylactic acid for surgical implants. Arch Surg 93:839–843PubMed Kulkarni RK, Pani KC, Neuman C, Leonard F (1966) Polylactic acid for surgical implants. Arch Surg 93:839–843PubMed
10.
go back to reference Schakenraad JM, Dijkstra PJ (1991) Biocompatibility of poly (dl-lactic acid/glycine) copolymers. Clin Mater 7:253–269PubMedCrossRef Schakenraad JM, Dijkstra PJ (1991) Biocompatibility of poly (dl-lactic acid/glycine) copolymers. Clin Mater 7:253–269PubMedCrossRef
11.
go back to reference Schakenraad JM, Hardonk MJ, Feijen J, Molenaar I, Nieuwenhuis P (1990) Enzymatic activity toward poly(l-lactic acid) implants. J Biomed Mater Res 24:529–545PubMedCrossRef Schakenraad JM, Hardonk MJ, Feijen J, Molenaar I, Nieuwenhuis P (1990) Enzymatic activity toward poly(l-lactic acid) implants. J Biomed Mater Res 24:529–545PubMedCrossRef
12.
go back to reference Bostman OM (1991) Absorbable implants for the fixation of fractures. J Bone Joint Surg Am 73:148–153PubMed Bostman OM (1991) Absorbable implants for the fixation of fractures. J Bone Joint Surg Am 73:148–153PubMed
13.
go back to reference Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399–404PubMed Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399–404PubMed
14.
go back to reference Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, Okada M, Nakamura T, Komori H, Motohara S, Uehata H (2001) Biodegradable polymeric stents. Curr Interv Cardiol Rep 3:10–17PubMedCrossRef Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, Okada M, Nakamura T, Komori H, Motohara S, Uehata H (2001) Biodegradable polymeric stents. Curr Interv Cardiol Rep 3:10–17PubMedCrossRef
15.
go back to reference Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, von Dahl J, Bosserhoff AK, Michaeli W, Hanrath P, Weber C, Blindt R (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330–1340PubMedCrossRef Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, von Dahl J, Bosserhoff AK, Michaeli W, Hanrath P, Weber C, Blindt R (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330–1340PubMedCrossRef
16.
go back to reference Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780–786PubMedCrossRef Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780–786PubMedCrossRef
17.
go back to reference Robey TC, Eiselt PM, Murphy HS, Mooney DJ, Weatherly RA (2000) Biodegradable external tracheal stents and their use in a rabbit tracheal reconstruction model. Laryngoscope 110:1936–1942PubMedCrossRef Robey TC, Eiselt PM, Murphy HS, Mooney DJ, Weatherly RA (2000) Biodegradable external tracheal stents and their use in a rabbit tracheal reconstruction model. Laryngoscope 110:1936–1942PubMedCrossRef
18.
go back to reference Chepurov AK, Krivoborodov GG, Zubarev AV, Zaitsev NV, Markina N (2003) Biodegradable ureteral stents in treating patients with infravesical obstruction. Urologiia 44–50 Chepurov AK, Krivoborodov GG, Zubarev AV, Zaitsev NV, Markina N (2003) Biodegradable ureteral stents in treating patients with infravesical obstruction. Urologiia 44–50
19.
go back to reference Knutson T, Pettersson S, Dahlstrand C (2002) The use of biodegradable PGA stents to judge the risk of post-TURP incontinence in patients with combined bladder outlet obstruction and overactive bladder. Eur Urol 42:262–267PubMedCrossRef Knutson T, Pettersson S, Dahlstrand C (2002) The use of biodegradable PGA stents to judge the risk of post-TURP incontinence in patients with combined bladder outlet obstruction and overactive bladder. Eur Urol 42:262–267PubMedCrossRef
Metadata
Title
Novel Biodegradable Stents for Benign Esophageal Strictures Following Endoscopic Submucosal Dissection
Authors
Yasuharu Saito
Toyohiko Tanaka
Akira Andoh
Hideki Minematsu
Kazunori Hata
Tomoyuki Tsujikawa
Norihisa Nitta
Kiyoshi Murata
Yoshihide Fujiyama
Publication date
01-02-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9873-6

Other articles of this Issue 2/2008

Digestive Diseases and Sciences 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.